Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy
Not Applicable
Completed
- Conditions
- Parathyroid NeoplasmsParathyroid HyperplasiaPrimary HyperparathyroidismParathyroid AdenomaParathyroid CancerHypercalcemia
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT04299425
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.
Not Applicable
Completed
- Conditions
- Thyroid NeoplasmsPostoperative HypoparathyroidismThyroid Cancer
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT04281875
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
Not Applicable
Active, not recruiting
- Conditions
- Lung Nodule
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 256
- Registration Number
- NCT04250194
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸Kootenai Health, Coeur d'Alene, Idaho, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation
Not Applicable
Terminated
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04146779
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Central Pain Syndrome in Survivors of Head and Neck Cancer
Not Applicable
Terminated
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04128267
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Not Applicable
Terminated
- Conditions
- Neuroendocrine TumorCarcinoid Syndrome
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT04073017
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
PCRC-Supported Legacy Intervention in Pediatric Palliative Care
Not Applicable
Completed
- Conditions
- Care GiverRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT04059393
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Yoga Intervention in Supporting Children With Cancer and Their Parents During Chemotherapy Infusion
Not Applicable
Terminated
- Conditions
- Malignant Neoplasm
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04034914
- Locations
- 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeMyelodysplastic SyndromeRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727Drug: IDH-1 Inhibitor FT-2102
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT04013880
A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
Early Phase 1
Completed
- Conditions
- Estrogen Receptor-positive Breast Cancer
- Interventions
- Dietary Supplement: 2-Week Ketogenic Diet
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03962647
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States